However, The findings of our meta-analysis indicate that while combination therapy with PD-1/PD-L1 inhibitors and anti-angiogenic agents significantly improves overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), these benefits come at the cost of an increased incidence of adverse events (AEs). The gene discussed is CD274; the disease is hepatocellular carcinoma.